This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

NPS Pharma Blames Winter, Drug Stops for Weak First Quarter, Reduced Guidance

NPS Pharmaceuticals (NPSP) reported first-quarter net sales of Gattex totaling $17.9 million, a consensus miss which the company blames on bad winter weather and a rise in the number of patients discontinuing therapy.

The slow start to the year means NPS Pharma is also reducing Gattex sales guidance for the year to a range of $100-110 million from $110-120 million. The current Gattex sales consensus estimate for 2014 is around $120 million.

NPS shares are off 17% to $22.50 in pre-market trading. 

Gattex treats short bowel syndrome, a chronic and disabling condition that strikes people, who for various reasons including Crohn's disease, have about 50% of their lower intestines surgically removed, forcing them to rely heavily on intravenous parenteral nutrition. Gattex is a given as a shot under the skin and boosts the ability of the intestine to absorb nutrients.

NPS Pharma is the second marketer of drugs for rare, orphan disease in the past two days to report weaker-than-expected sales in the March quarter and take down financial guidance. Wednesday, Aegerion Pharmaceuticals (AEGR) did the same thing and its stock fell 22% to $34.63 as a result

Gattex's sales miss for the first quarter was only $1.5 million, not huge, and the company says sales metrics bounced back in March and April. If the Gattex slowdown is no longer a problem, why is NPS Pharma cutting $10 million in Gattex revenue from its year-end forecast? 

"We're a conservative company. I'd rather under promise and over deliver," said NPS Pharma CEO Francois Nader, in an interview Wednesday night. 

That may be true but expect investors to focus on the rising Gattex discontinuation rate as a potential hot spot. Approximately 10% of patients stopped Gattex therapy at the end of the year. The discontinuation rate in the first quarter was higher although NPS Pharma will not disclose the exact number. 

"We always expected the [Gattex] discontinuation rate to increase over time to between 20-30%, but the increase in the first quarter impacted sales," said Nader. He adds that patients stop taking Gattex because of gastrointestinal side effects (abdominal pain, nausea and vomiting), and because they wean themselves off the drug after reducing parenteral nutrition.  [These latter patients might return to Gattex when they once again require parenteral nutrition.]

In an interview conducted for investor clients of J.P. Morgan on March 27, Nader discussed the Gattex discontinuation issue but made no mention of higher rates in the first quarter negatively impacting sales or forcing the company to reduce 2014 guidance, according to a transcript. 

NPS Pharma's net loss for the quarter narrowed to $6.6 million, or 6 cents per share, compared to a net loss of $7.8 million, or 9 cents per share, one year ago. Total revenue in the quarter was  $44 million, which is comprised of product sales and royalties. In the year-ago quarter, total revenue was $25.4 million. 

NPS Pharma shares closed Wednesday at $27.04, ahead of the earnings announcement. 






Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,156.85 +24.88 0.15%
S&P 500 2,001.57 +2.59 0.13%
NASDAQ 4,562.1890 +9.43 0.21%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs